Skip to main content
Top
Published in: BMC Women's Health 1/2021

Open Access 01-12-2021 | Breast Cancer | Case report

Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature

Authors: Sawsan Ismail, Haidara Kherbek, Jana Skef, Nadim Zahlouk, Rafik Abdulal, Zuheir Alshehabi

Published in: BMC Women's Health | Issue 1/2021

Login to get access

Abstract

Background

Apocrine carcinoma is a rare tumor that constitutes < 4% of all breast malignancies, characterized by the proliferation of large atypical cells with strictly defined borders, abundant eosinophilic cytoplasm, large nuclei, and prominent nucleoli in more than 90% of tumor cells. Triple-negative apocrine carcinoma is a rare molecular subtype that constitutes less than 1% of triple-negative breast cancers and is characterized by negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor, with positive expression of androgen receptor.

Case presentation

We report a case of a 45-year-old Syrian female who presented to our hospital due to a painless palpable mass in her left breast. Following physical and radiological examinations, an excisional biopsy was performed. Microscopic examination of the specimen followed by immunohistochemical staining revealed the diagnosis of a triple-negative apocrine carcinoma.

Conclusion

Triple-negative apocrine carcinoma is an extremely rare neoplasm that must be considered in the differential diagnoses of breast lesions through detailed clinical, histological, and immunohistochemical correlations. In our manuscript, we aimed to present the first case report of a Syrian female who was diagnosed with a triple-negative apocrine carcinoma, aiming to highlight the importance of detailed clinical, histological and immunohistochemical correlations with a detailed review of diagnostic criteria, molecular characteristics, and treatment recommendations.
Literature
1.
go back to reference Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28:1393–409.PubMed Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28:1393–409.PubMed
3.
go back to reference Liao HY, Zhang WW, Sun JY, et al. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9(2):296–303. Published 2018 Jan 1. doi:https://doi.org/10.7150/jca.22280 Liao HY, Zhang WW, Sun JY, et al. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer. 2018;9(2):296–303. Published 2018 Jan 1. doi:https://​doi.​org/​10.​7150/​jca.​22280
5.
go back to reference Krompecher E. Zur histogene und morphologie der cystenmamma (maldie kystique reclus, cystadenoma schimmelbuscin, mastitis chronica cystic konig) des intrakanaliken kystadenomas und der kystadenokarzinome der brustdruse (hidrokystoma, kystoadenoma, hidrokystadenocarzinoma mammae). Beitr Pathol Anat. 1916;62:403–10. Krompecher E. Zur histogene und morphologie der cystenmamma (maldie kystique reclus, cystadenoma schimmelbuscin, mastitis chronica cystic konig) des intrakanaliken kystadenomas und der kystadenokarzinome der brustdruse (hidrokystoma, kystoadenoma, hidrokystadenocarzinoma mammae). Beitr Pathol Anat. 1916;62:403–10.
6.
go back to reference Japaze H, Emina J, Diaz C, et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast. 2005;14:3–10.CrossRef Japaze H, Emina J, Diaz C, et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast. 2005;14:3–10.CrossRef
7.
go back to reference Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma-rare types; review of the literature. Ann Oncol 2009;20:1763e70. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma-rare types; review of the literature. Ann Oncol 2009;20:1763e70.
8.
go back to reference Onoue S, Katoh T, Chigira H, et al. A case of apocrine carcinoma of the breast presenting as two cysts. Breast Cancer. 1997;4:193–6.CrossRef Onoue S, Katoh T, Chigira H, et al. A case of apocrine carcinoma of the breast presenting as two cysts. Breast Cancer. 1997;4:193–6.CrossRef
9.
go back to reference Gokalp G, Topal U, Haholu A, et al. Apocrine carcinoma of the breast: mammography and ultrasound findings. Eur J Radiol Extra. 2006;60:55–9.CrossRef Gokalp G, Topal U, Haholu A, et al. Apocrine carcinoma of the breast: mammography and ultrasound findings. Eur J Radiol Extra. 2006;60:55–9.CrossRef
12.
go back to reference Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205–12.CrossRef Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23:205–12.CrossRef
13.
go back to reference Tavassoli FA, Purcell CA, Bratthauer GL, et al. Androgen receptor expression along with loss of Bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications of therapy. Breast J. 1996;2:261–9.CrossRef Tavassoli FA, Purcell CA, Bratthauer GL, et al. Androgen receptor expression along with loss of Bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications of therapy. Breast J. 1996;2:261–9.CrossRef
14.
go back to reference Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–71.CrossRef Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–71.CrossRef
15.
go back to reference Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10:542–8.CrossRef Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia. 2008;10:542–8.CrossRef
16.
go back to reference Naderi A, Meyer M. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 2012;14:R111.CrossRef Naderi A, Meyer M. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 2012;14:R111.CrossRef
20.
go back to reference Tarulli GA, Butler LM, Tilley WD, et al. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer. 2014;21(4):T183-202.CrossRef Tarulli GA, Butler LM, Tilley WD, et al. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer. 2014;21(4):T183-202.CrossRef
21.
go back to reference Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.CrossRef Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–12.CrossRef
22.
go back to reference Lehmann BDBJA, Schafer JM, Pendleton CS, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:1–16.CrossRef Lehmann BDBJA, Schafer JM, Pendleton CS, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:1–16.CrossRef
23.
go back to reference Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–72.CrossRef Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–72.CrossRef
Metadata
Title
Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature
Authors
Sawsan Ismail
Haidara Kherbek
Jana Skef
Nadim Zahlouk
Rafik Abdulal
Zuheir Alshehabi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-021-01539-3

Other articles of this Issue 1/2021

BMC Women's Health 1/2021 Go to the issue